Last reviewed · How we verify
clonidine gel 1%
Clonidine is an alpha-2 adrenergic agonist that decreases sympathetic nervous system activity.
Clonidine is an alpha-2 adrenergic agonist that decreases sympathetic nervous system activity. Used for Hypertension, Attention deficit hyperactivity disorder (ADHD), Menopausal flushing.
At a glance
| Generic name | clonidine gel 1% |
|---|---|
| Sponsor | Irmandade da Santa Casa de Misericordia de Sao Paulo |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By activating alpha-2 adrenergic receptors in the brain, clonidine reduces the release of norepinephrine, leading to decreased sympathetic nervous system activity. This results in decreased heart rate, blood pressure, and anxiety.
Approved indications
- Hypertension
- Attention deficit hyperactivity disorder (ADHD)
- Menopausal flushing
Common side effects
- Dry mouth
- Dizziness
- Fatigue
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clonidine gel 1% CI brief — competitive landscape report
- clonidine gel 1% updates RSS · CI watch RSS
- Irmandade da Santa Casa de Misericordia de Sao Paulo portfolio CI